BioWorld Asia

Nov. 14, 2007

Antisense Pharma Gets $39.5M For Antisense Glioma Product

Antisense Pharma GmbH raised €27 million (US$39.5 million) in a third investment round funded solely by MIG AG, which also was the only investor in its €18 million funding round two years ago. (BioWorld International) Read More

Acambis Partners West Nile Vaccine In $80M Sanofi Deal

Novel Obesity Gene Plays A Role In Modifying DNA

Actelion Advances Clazosentan Into Phase III Vasospasm Study

Peptech Reinvents Itself As Arana, Shifts To Antibodies

Cerep Sells Hesperion To CRO Averion In €25M Deal

No Abstract Read More

Activists Strike At European Industry's Lobbying Power

Other News To Note

LSD Deal Brings Amicus $50M Now, $390M Later

As Big Pharma Model Falters, Biotech Rides To The Rescue

Today's news in brief

BioWorld

BioWorld briefs for June 22, 2026.

Alicorn synthesizes new AAK1 inhibitors

BioWorld Science

Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...

Illustration of glucose in the blood stream

CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research

BioWorld Science

Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...

Saniona reports preclinical data for SAN-2668

BioWorld Science

Saniona AB has presented preclinical data and its clinical development strategy for its lead clinical candidate, SAN-2668, which is a GABA-A receptor positive...

Insilico Medicine synthesizes new Nav1.8 blockers

BioWorld Science

Insilico Medicine Inc. has identified sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers that are potentially useful for the treatment of pain.